Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 19/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.74 |
| ▸ | TNF | P01375 | 3/20 | 0.74 |
| ▸ | IL1B | P01584 | 3/20 | 0.74 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avadomide SCHEMBL15120730 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442249 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29359950 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL634577 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL282749 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20456410 | 0.84 | CRBN (0.52) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL12099722 | 0.84 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29519996 | 0.84 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29520051 | 0.84 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15515920 | 0.84 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018144445-A1 | METHODS FOR TREATING HEMATOLOGICAL CANCER AND THE USE OF BIOMARKERS AS A PREDICTOR FOR RESPONSIVENESS TO TREATMENT COMPOUNDS | CELGENE CORPORATION (US) | 2018-08-09 | — | — | WO | disclosed |